IMPROVEMENTS IN SELECT PATIENT-REPORTED OUTCOMES ARE SIMILAR ACROSS DIFFERENT OMALIZUMAB DOSING REGIMENS

For patients with asthma, the dose/frequency of omalizumab is determined by bodyweight and pretreatment IgE levels. Since patients who fall outside the dosing table are treated with omalizumab, we assessed patient-reported outcomes (Asthma Control Test [ACT], Global Evaluation of Treatment Effectiveness [GETE], Work Productivity and Activity Impairment [WPAI-Asthma]) stratified by where they fell on the omalizumab dosing table.